L575-0392 Screening compound: 4-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxo-N-[3-(piperidin-1-yl)propyl]butanamide

L575-0392 Screening compound: 4-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxo-N-[3-(piperidin-1-yl)propyl]butanamide
L575-0392 Screening compound: 4-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxo-N-[3-(piperidin-1-yl)propyl]butanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L575-0392
4-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxo-N-[3-(piperidin-1-yl)propyl]butanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L575-0392

Molecular Formula

C25H40N6O3 (C25 H40 N6 O3)

Compound Name

4-[1-methyl-3-(piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxo-N-[3-(piperidin-1-yl)propyl]butanamide

IUPAC name

4-[1-methyl-3-(piperidine-1-carbonyl)-1H4H5H6H7H-pyrazolo[43-c]pyridin-5-yl]-4-oxo-N-[3-(piperidin-1-yl)propyl]butanamide

SMILES

Cn1nc(C(N2CCCCC2)=O)c(C2)c1CCN2C(CCC(NCCCN1CCCCC1)=O)=O

InChI

InChI=1S/C25H40N6O3/c1-28-21-11-18-31(19-20(21)24(27-28)25(34)30-16-6-3-7-17-30)23(33)10-9-22(32)26-12-8-15-29-13-4-2-5-14-29/h2-19H2,1H3,(H,26,32)

InChI Key

BPXXZTKOTJFMSR-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27643092

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

472.63

Hydrogen Bond Acceptors Count

8.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

11.00

Number of Nitrogen and Oxygen Atoms

9

Partition Coefficient, logP

-0.194

Distribution Coefficient, logD

-2.848

Water Solubility, LogSw

-0.04

Polar Surface Area

75.983

Acid Dissociation Constant (pKa)

15.45

Base Dissociation Constant (pKb)

10.05

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

76.00

L575-0392 in Drug Discovery

Included in Screening Libraries

3D-Pharmacophore Based Diversity Library (49813 compounds)

Anticancer Library (62698 compounds)

Cysteine Proteases Inhibitors Library (7839 compounds)

GPCR Targeted Library (31838 compounds)

Hsp90-Targeted Library (11355 compounds)

MCL1 Targeted Library (12200 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Nervous system
  • Cardiovascular
  • Skin
  • Metabolic
  • Endocrine
  • Immune system
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
  • Cancer
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Immune system
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
Targets:
  • Proteases
  • GPCR
Mechanism of action:
  • Receptor's ligands

References: we are preparing a list of scientific research reports with L575-0392 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L575-0392?
Check Price and Availability of L575-0392, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L575-0392 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L575-0392
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L575-0392
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L575-0392 available by request